SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Diabetes
Products
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Rights Issue
Skip Navigation Links
Home
»
Investors
»
Press Releases
Diamyd Medical’s financial year comprises 1 September – 31 August.
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Data pager
Data pager
1
2
3
4
Show:
PageSizeComboBox
select
10
20
50
100
150
4 pages
Press Releases
Data pager
Data pager
1
2
3
4
Show:
PageSizeComboBox
select
10
20
50
100
150
4 pages
12/6/2023
Diamyd Medical's Precision Medicine patent for the prevention and treatment of autoimmune diabetes granted in South Korea
11/30/2023
Bulletin from Annual General Meeting of Diamyd Medical AB
11/29/2023
Annual Report 2022/2023
11/9/2023
Information about the Annual Report 2022/23
11/7/2023
Diamyd Medical partners with DiaUnion to recruit participants for Type 1 diabetes prevention trial
11/1/2023
Diamyd Medical announces final outcome in the company’s rights issue
10/31/2023
Diamyd Medical announces preliminary outcome in the company’s rights issue
10/26/2023
Follow-up study suggests Diamyd
®
may offer advantages in delaying type 1 diabetes onset
10/20/2023
Preliminary results from Booster trial with Diamyd
®
provide additional support for intralymphatic injections
10/17/2023
Diamyd Medical announces a webcast presentation on October 20 regarding its industry partnership with JDRF
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research